Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration.

Stephen G Schwartz, Milam A Brantley, Jaclyn L Kovach, Andrzej Grzybowski

Journal: Current pharmaceutical design 2017;23(4):547-550

PMID: 27928964

Abstract

Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.

Address: Bascom Palmer Eye Institute at Naples, 3880 Tamiami Trail North, Naples, FL 34103. United States.; Department of Ophthalmology, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN. United States.; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL. United States.; Department of Ophthalmology, University of Warmia and Mazury, Olsztyn. Poland.

DOI: 10.2174/1381612822666161208114847

Link outs

Free resources

Medical:

https://medlineplus.gov/dietarysupplements.html

Other Literature Sources:

https://scite.ai/reports/27928964

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-2658

Subscription / membership required

Full Text Sources:

MeSH Terms: Age Factors, Angiogenesis Inhibitors, Dietary Supplements, Humans, Macular Degeneration, Pharmacogenetics, Vascular Endothelial Growth Factors